Arcalyst for Gout under Review by FDA
November 29, 2011 by Estella .
Regeneron Pharmaceuticals Inc. announced that FDA will review its drug Arcalyst as a treatment for gout. FDA plans to complete this review by July 30, 2012.
from Regeneron Pharm
Arcalyst (rilonacept) is currently approved to treat Cryopyrin-Associated Periodic Syndromes (CAPS), a rare genetic anti-inflammatory disease. Regeneron reported $5.5 million in sales of the drug during the third quarter.
Regeneron is a fully integrated biopharmaceutical company markets two main products: Arcalyst (rilonacept) injection for subcutaneous use and Zaltrap (aflibercep) injection. Additional information about Regeneron and recent news releases are available at www.regeneron.com.
Filed under: Gout Treatment and Prevention, Gout Medications.
Tags: arcalyst, rilonacep, fda review, gout treatment, gouty arthritis, new gout drug.
Leave your comment: